Phase I Study of Cellular Immunotherapy Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Patients With Recurrent/Refractory Malignant Glioma
Phase of Trial: Phase I
Latest Information Update: 27 Nov 2017
At a glance
- Drugs MB 101 (Primary)
- Indications Glioblastoma; Glioma
- Focus Adverse reactions
- 21 Nov 2017 Planned number of patients changed from 100 to 135.
- 11 Oct 2017 According to a Mustang Bio media release, this trial has recieved a $12.8 million grant from the California Institute for Regenerative Medicine (CIRM). This grant will enable the expansion of this trial to continue to explore the most effective delivery methods of MB-101.
- 22 Aug 2017 According to a Mustang Bio media release, the company expects to read-out data from this study in early 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History